Список литературы

1. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview.//Nat Rev Gastroenterol Hepatol. - 2009 - V. 6, N 12. - P. 699 - 708.

2. Wolpin BM, Ng K, Bao Y, Kraft P, Stampfer MJ et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer.//Cancer Epidemiol Biomarkers Prev. - 2012. - V. 21, N 1. - P. 82 - 91

3. Duell EJ, Lucenteforte E, Olson SH et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4).//Ann Oncol. - 2012. - V. 23, N 11. - P. 2964 - 70.

4. Huang Y, Cai X, Qiu M et al. Prediabetes and the risk of cancer: a meta-analysis.//Diabetologia. - 2014. - V. 57, N 11. - P. 2261 - 9.

5. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г./М.: Издательская группа РОНЦ, 2014. - 226 с.

6. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study.//J Clin Oncol. - 2011. - V. 29. - P. 3457 - 3465

7. Tempero M., Malafa M., Al-Hawary M. et al. NCCN Clinical practice guidelines in oncology. Pancreatic adenocarcinoma. V. 2.2016./Published online https://www.nccn.org/professionals/physician_gls/f_guidelines.asp (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

8. Li JH, He R, Li YM et al. Endoscopic ultrasonography for tumor node staging and vascular invasion in pancreatic cancer: a meta-analysis. Dig Surg. - 2014. - V. 31, N 4 - 5. - P. 297 - 305 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

9. Agarwal B, Abu-Hamda E, Molke KL et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer.//Am J Gastroenterol. - 2004. - 99, N 5. - P. 844 - 50. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

10. Wyse JM, Carone M, Paquin SC et al. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer.//J Clin Oncol. - 2011. - V. 29, N 26. - P. 3541 - 6 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

11. Farma JM, Santillan AA, Melis M et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.//Ann Surg Oncol. - 2008. - V. 15, N 9. - P. 2465 - 71. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

12. Daly M., Pilarski R., Berry M. et al. NCCN Clinical practice guidelines in oncology. Genetic/familial high-risk assessment: breast and ovarian. V. 2. 2017/Published online (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp) https://www.nccn.org/professionals/physician_gls/f_guidelines. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

13. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial.//JAMA - 2007. - N 297. - P. 267 - 277 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

14. Патютко Ю.И., Кудашкин Н.Е., Котельников А.Г. Гепатопанкреатодуоденальная резекция - есть ли перспективы?//Хирургия. Журнал им. Н.И. Пирогова. - 2011. - N 8. - С. 41 - 46. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

15. Патютко Ю.И., Кудашкин Н.Е., Поляков А.Н., Абиров К.А., Подлужный Д.В. Проксимальная и дистальная резекция поджелудочной железы с сохранением тела.//Хирургия. Журнал им. Н.И. Пирогова. - 2012. - N 2 - С. 70 - 73. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

16. Патютко Ю.И., Котельников А.Г., Кудашкин Н.Е., Агафонова М.Г. Резекция сосудов в хирургии рака поджелудочной железы.///Вестник хирургической гастроэнтерологии. - 2012. - N 3 - с. 21 - 32 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

17. Varadhachary G.R., Tamm E.P., Abbruzzese J.L. et al. Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy.//Annals of Surgical Oncology. - 2006. - V. 13, N 8. - P. 1035 - 1046. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

18. Патютко Ю.И., Кудашкин Н.Е., Котельников А.Г., Чистякова О.В. Тотальная панкреатэктомия при опухолевом поражении поджелудочной железы.//Хирургия. Журнал им. Н.И. Пирогова. - 2016. - N 9 - С. 13 - 20 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

19. Базин И.С., Покатаев И.А., Попова А.С. и соавт. Место химиотерапии в лечении локализованного рака поджелудочной железы//Злокачественные опухоли. - 2016. - Т. 21, N 4 (спецвыпуск 1). - С. 20 - 25. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

20. Massucco P, (https://www.ncbi.nlm.nih.gov/pubmed/? term=Massucco%20P%5BAuthor%5D&cauthor=true&cauthor_uid=16955382)Capussotti L, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Capussotti%20L%5BAuthor%5D&cauthor=true&cauthor_uid=16955382)Magnino A et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Magnino%20A%5BAuthor%5D&cauthor=true&cauthor_uid=16955382)Ann Surg Oncol. - 2006. - V. 13, 9. - P. 1201 - 8. (https://www.ncbi.nlm.nih.gov/pubmed/16955382)

21. Liao WC1, (https://www.ncbi.nlm.nih.gov/pubmed/? term=Liao%20WC%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)Chien KL, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Chien%20KL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)Lin YL et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis.//Lancet Oncol. - 2013. - V. 14, N 11. - P. 1095 - 103. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lin%20YL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)

22. Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014 Feb 20; 32(6): 504 - 12 (https://www.ncbi.nlm.nih.gov/pubmed/? term=Lin%20YL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)

23. Neoptolemos J.P., Moore M.J., Cox T.F. et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11; 308(2): 147 - 56. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lin%20YL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)

24. Neoptolemos J., Palmer D., Ghaneh P. et al. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 34, 2016 (suppl; abstr LBA4006) (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lin%20YL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)

25. Покатаев И.А., Тюляндин С.А. Системная лекарственная терапия метастатического рака поджелудочной железы. - Современная онкология. - 2016. - N 1. - С. 20 - 24. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lin%20YL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)

26. Burris HA 3rd, Moore MJ, Andersen J et al. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Lin%20YL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.//J Clin Oncol. - 1997 - V. 15, N 6. - P. 2403 - 13. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)

27. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.//N Engl J Med. - 2011. - V. 364, 19. - P. 1817 - 25. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)

28. Von Hoff D., Ervin T., Arena F. et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine.//N Engl J Med - 2013. V. 369. - P. 1691 - 703. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)

29. Fogelman D., Sugar E.A., Oliver G. et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.//Cancer Chemother Pharmacol. - 2015. - V. 76, N 3. - P. 489 - 98. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)

30. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.//J Clin Oncol. - 2007 - V. 25, N 15. - P. 1960 - 6. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)

31. Boeck S, Wilkowski R, Bruns CJ, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.//Oncology - 2007. - N. 73. - P. 221 - 7. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)

32. Novarino A, Satolli MA, Chiappino I, et al. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.//Am J Clin Oncol - 2009. - V. 32. - P. 44 - 8 (https://www.ncbi.nlm.nih.gov/pubmed/9196156)

33. Xiong HQ, Varadhachary GR, Blais JC, et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.//Cancer - 2008. - N 113. - P. 2046 - 52 (https://www.ncbi.nlm.nih.gov/pubmed/9196156)

34. Neuzillet C, Hentic O, Rousseau B, et al. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemctabine and platinum-salts.//World J Gastroenterol - 2012. - N 18. - P. 4533 - 41 (https://www.ncbi.nlm.nih.gov/pubmed/9196156)

35. Van der Gaag NA, Rauws EA, van Eijck CH et al. Preoperative biliary drainage for cancer of the head of the pancreas.//N Engl J Med - 2010. - N 362. - P. 129 - 137 (https://www.ncbi.nlm.nih.gov/pubmed/9196156)

36. Кудашкин Н.Е., Агафонова М.Г., Котельников А.Г., Патютко Ю.И. Стратегия радикального лечения опухолей периампулярной локализации, осложненных механической желтухой.//Фарматека. - 2012. - N 8(241) - С. 7781. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)

37. Maire F1, Hammel P, Ponsot P et al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas.//Am J Gastroenterol. - 2006. - V. 101, N 4. - P. 735 - 42. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Maire%20F%5BAuthor%5D&cauthor=true&cauthor_uid=16635221)

38. Jeurnink SM, Steyerberg EW, Hof Gv et al. Gastrojejunostomy versus stent placement in patients with malignant gastric outlet obstruction: a comparison in 95 patients.//J Surg Oncol. - 2007. - V. 96, N 5. - P. 389 - 96. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Maire%20F%5BAuthor%5D&cauthor=true&cauthor_uid=16635221)

39. Wong GY, Schroeder DR, Carns PE et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial.//JAMA. - 2004. - V. 291, N 9. - P. 1092 - 9. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Maire%20F%5BAuthor%5D&cauthor=true&cauthor_uid=16635221) (https://www.ncbi.nlm.nih.gov/pubmed/?term=Maire%20F%5BAuthor%5D&cauthor=true&cauthor_uid=16635221) (https://www.ncbi.nlm.nih.gov/pubmed/?term=Maire%20F%5BAuthor%5D&cauthor=true&cauthor_uid=16635221)